Tharimmune : Submission of Matters to a Vote of Security Holders - Form 8-K
October 24, 2023 at 04:19 pm EDT
Share
Item 5.07 Submission of Matters to a Vote of Security Holders.
On October 23, 2023, Tharimmune, Inc. (the "Company") held its 2023 annual meeting of stockholders (the "Annual Meeting"). A total of 10,937,815 shares of the Company's common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Company's Definitive Proxy Statement, filed with the Securities and Exchange Commission on August 30, 2023, are as follows:
Proposal 1. At the Annual Meeting, five nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. The result of the votes to elect the five directors were as follows:
Directors
For
Abstain
Broker Non-Votes
Randy Milby
8,314,605
193,390
2,429,820
Leonard Mazur
8,358,930
149,108
2,429,777
Lynne A. Bui
7,823,648
684,390
2,429,777
Sireesh Appajosyula
8,313,024
194,971
2,429,820
Kelly Anderson
8,315,552
192,486
2,429,777
Proposal 2. At the Annual Meeting, the stockholders approved the ratification of the appointment of Rosenberg Rich Baker Berman P.A. ("RRBB") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The result of the votes to approve RRBB was as follows:
For
Against
Abstain
10,732,062
203,030
2,723
Proposal 3. At the Annual Meeting, the stockholders approved the Company's 2023 Omnibus Equity Incentive Plan (the "2023 Plan"). The result of the votes to approve the 2023 Plan was as follows:
For
Against
Abstain
Broker
Non-Votes
8,129,962
375,606
2,470
2,429,777
Proposal 4. At the Annual Meeting, the stockholders approved granting discretionary authority to the Company's board of directors to (A) amend the Company's Certificate of Incorporation, as amended, to effect one or more consolidations of the issued and outstanding shares of common stock of the Company pursuant to which the shares of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-2 up to 1-for-50 (the "Reverse Stock Split") and (B) arrange for the disposition of fractional interests by stockholders entitled thereto by entitling such stockholders to receive from the Company's transfer agent, in lieu of any fractional share, the number of shares of common stock rounded up to the next whole number, provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate, exceed 1-for-50, and (Y) any Reverse Stock Split is completed no later than October 23, 2024. The result of the votes to approve the Reverse Stock Split proposal was as follows:
Hillstream BioPharma Inc. published this content on 24 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2023 20:18:01 UTC.
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.